20. October 2015
Press release: Additional subsidy funding for clinical development of a celiac disease drug
Read more | Document

20. October 2015
Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
Read more | Document

29. September 2015
New: Recombinant Gliadin Peptides
Read more | Document

22. September 2015
Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
Read more | Document

18. June 2015
New website launched
Read more | Document

02. March 2015
Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
Read more | Document

02. March 2015
Pressemitteilung: Dr. Falk Pharma und Zedira starten klinische Phase I zur medikamentösen Behandlung der Zöliakie
Read more | Document

03. February 2015
Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
Read more | Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 27th ISTH Congress

    06.06.2019 - 10.06.2019
    Melbourne, Australia

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

  • Workshop on Transglutaminase Research

    28.09.2019 - 01.10.2019
    Marrakech, Morocco